Literature DB >> 26840146

Nivolumab in Nonsquamous Non-Small-Cell Lung Cancer.

Bishal Gyawali, Akiko Ota, Yuichi Ando.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26840146     DOI: 10.1056/NEJMc1514790

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  4 in total

1.  A new era of treating advanced lung cancer is upon us.

Authors:  Glen J Weiss
Journal:  Transl Lung Cancer Res       Date:  2018-09

2.  The Clinical and Biomarker Association of Programmed Death Ligand 1 and its Spatial Heterogeneous Expression in Colorectal Cancer.

Authors:  Xiao-Li Wei; Qi-Nian Wu; Dong-Liang Chen; Zhao-Lei Zeng; Jia-Bin Lu; Ze-Xian Liu; Huai-Qiang Ju; Chao Ren; Zhi-Zhong Pan; Feng-Hua Wang; Rui-Hua Xu
Journal:  J Cancer       Date:  2018-10-21       Impact factor: 4.207

3.  Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for treatment of recurrent or metastatic head and neck squamous cell carcinoma: a systematic review and network meta-analysis.

Authors:  Zhe Jin; Bin Zhang; Lu Zhang; Wenhui Huang; Xiaokai Mo; Qiuyin Chen; Fei Wang; Zhuozhi Chen; Minmin Li; Shuixing Zhang
Journal:  Ther Adv Med Oncol       Date:  2020-12-26       Impact factor: 8.168

4.  A Comparison of Response Patterns for Progression-Free Survival and Overall Survival Following Treatment for Cancer With PD-1 Inhibitors: A Meta-analysis of Correlation and Differences in Effect Sizes.

Authors:  Bishal Gyawali; Spencer Phillips Hey; Aaron S Kesselheim
Journal:  JAMA Netw Open       Date:  2018-06-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.